Financial Analysis: Cascadian Therapeutics (CASC) & The Competition
Cascadian Therapeutics (NASDAQ: CASC) is one of 292 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Cascadian Therapeutics to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.
This is a summary of current ratings for Cascadian Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cascadian Therapeutics Competitors||741||2976||11076||223||2.72|
Cascadian Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 37.93%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 31.83%. Given Cascadian Therapeutics’ higher possible upside, analysts clearly believe Cascadian Therapeutics is more favorable than its rivals.
This table compares Cascadian Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cascadian Therapeutics Competitors||-5,527.68%||-454.18%||-42.49%|
Valuation and Earnings
This table compares Cascadian Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cascadian Therapeutics||N/A||-$47.29 million||-2.70|
|Cascadian Therapeutics Competitors||$258.58 million||$65.85 million||-7.26|
Cascadian Therapeutics’ rivals have higher revenue and earnings than Cascadian Therapeutics. Cascadian Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Cascadian Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Cascadian Therapeutics’ rivals have a beta of 6.66, meaning that their average stock price is 566% more volatile than the S&P 500.
Institutional & Insider Ownership
82.6% of Cascadian Therapeutics shares are held by institutional investors. Comparatively, 50.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 1.1% of Cascadian Therapeutics shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cascadian Therapeutics rivals beat Cascadian Therapeutics on 7 of the 12 factors compared.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.